Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

30.12 +1.77 (+6.24%)
Official Closing Price Updated: 4:10 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
32 33 Next >
News headline image
Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27 ↗
Reuters Monkeypox Emergency Could Last Months, According To Experts 
Via Benzinga
News headline image
Alphabet, Microsoft And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗
Pzena Investment Management, Inc (NYSE: PZN) rose 46.4% to $9.43 in pre-market trading as the company said it has entered into an agreement to become a private company. The company also reported a rise... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Good morning, investor! Wednesday starts with a breakdown of the biggest pre-market stock movers for traders to keep an eye on! 
Via InvestorPlace
News headline image
What Is Going on With Teva Pharmaceuticals (TEVA) Stock Today? ↗
TEVA stock, already trading far below its prior peak, may come under pressure in the near future due to the threat of ongoing litigation. 
Via InvestorPlace
News headline image
Analyst Ratings for Teva Pharmaceutical Indus ↗
Within the last quarter, Teva Pharmaceutical Indus (NYSE:TEVA) has observed the following analyst ratings: 
Via Benzinga
News headline image
Why Is F45 Training Holdings Down By 56%? Here Are 28 Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Dave Inc. (NASDAQ: DAVE) rose 56.9% to $0.9826 in pre-market trading. Dave is expected to release its second quarter 2022 financial results on Thursday, August 11, 2022. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Why Teva Pharmaceuticals Stock Is Soaring After Hours ↗
Teva Pharmaceutical Industries (NYSE: TEVA) shares are surging in Tuesday's after-hours session after the company reported better-than-expected financial results. 
Via Benzinga
News headline image
Teva Reports Second Quarter 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
7 Growth Stocks to Buy on the Dip ↗
These are the best growth stocks to buy on the dip. A, CDNS, GXTG, IVSG, IQV, PAYX, and SNPS are poised to deliver impressive returns. 
Via InvestorPlace
News headline image
Will Bed Bath & Beyond (BBBY) Stock Really Fall to $1? ↗
Bed Bath & Beyond (BBBY) stock is in the news today after an incredibly bearish analyst said the retailer's shares will fall to $1 a piece. 
Via InvestorPlace
News headline image
Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
New York Attorney General Says Teva Tried To Evade Accountability On Opioid Crisis: Report ↗
Reuters reported that New York's attorney general said Teva Pharmaceutical Industries Ltd (NY 
Via Benzinga
News headline image
Teva Announces Appointment of New Global R&D and Chief Medical Officer
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)
From Teva Pharmaceutical Industries Ltd.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Golden Cross Appears Before Teva Pharmaceutical Indus Investors ↗
If history is any guide, there may be good fortune ahead for shares of Teva Pharmaceutical Indus (NYSE:TEVA). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
News headline image
Teva, Allergan Settle Opioid Lawsuit With West Virginia ↗
U.S. affiliate of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has reached an agreement with the Attorney General of West Virginia that settles the state's opioid-related claims. 
Via Benzinga
News headline image
Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients ↗
 
Via Benzinga
News headline image
BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal ↗
Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) stock, according to BofA Securities. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2022 ↗
 
Via Benzinga
News headline image
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.